Connect with us

Media OutReach

BeOne Medicines Recognized as “Outstanding Global Oncology Company of the Year” at HKCT Business Awards 2026

Published

on

HONG KONG SAR – Media OutReach Newswire – 11 May 2026 – BeOne Medicines (BeOne, Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has been named “Outstanding Global Oncology Company of the Year” at the HKCT Business Awards 2026. The award recognizes BeOne’s continued progress in research and development (R&D) and manufacturing of innovative cancer therapies, as well as its efforts to support broader patient access to medicines.

(Left) Richard Cheng, Associate Commercial Director (Hong Kong & Macau) at BeOne; (Right) Dr. Bernard Chan, JP, Under Secretary for Commerce and Economic Development

Richard Cheng, Associate Commercial Director (Hong Kong & Macau) at BeOne, said: “We are honored to receive this award from the Hong Kong Commercial Times. BeOne has built differentiated capabilities across clinical development and manufacturing, supported by a broad and diverse R&D pipeline. In Hong Kong, we have introduced several therapies, including BTK, PD-1 and IL-6 inhibitors. Looking ahead, we will continue to advance our plans in Hong Kong by leveraging opportunities enabled by the ‘1+’ policy and the planned establishment of the Hong Kong Centre for Medical Products Regulation (CMPR) and its ‘primary evaluation’ mechanism. Supported by our global supply network, we aim to bring additional medicines to patients in Hong Kong and the Greater Bay Area and help improve access to treatments aligned with international standards.”

Global R&D and Innovation

Founded in 2010, BeOne is focused on accelerating key stages of oncology innovation—from discovery through development to patient access. Through an integrated model spanning R&D, manufacturing and commercialization, the company works to translate innovation into clinical value. Today, BeOne operates across six continents in more than 45 markets and is supported by more than 1,200 oncology R&D professionals.

BeOne’s R&D platform has advanced more than 35 clinical-stage drug candidates, including three internally developed products that have received commercial approval, reaching more than 2 million patients worldwide.

Pipeline Highlights

BeOne continues to expand its global footprint through a portfolio of internally developed products, including:

  • BTK Inhibitor: As the company’s first self-developed innovative drug, it holds a significant position in the global market (including Hong Kong), particularly in the field of B-cell malignancies.
  • PD-1 Inhibitor: Launched in more than 50 markets worldwide, reaching 1.8 million people. In Hong Kong, it has been approved for six indications, including immunotherapy for lung, esophageal and gastric cancers.
  • Next-Generation BCL-2 Inhibitor: Approved for certain lymphoma indications in Mainland China. It has been granted Priority Review by the U.S. Food and Drug Administration, and a marketing application has been submitted in the European Union.

Manufacturing Network Supporting Global Supply

BeOne maintains an integrated chain from R&D to manufacturing and commercialization, supported by production sites in the United States and China designed to help maintain a stable global supply:

  • New Jersey, U.S.: A North America biologics hub integrating manufacturing and clinical R&D. The site spans 1.82 million square feet, including a dedicated 400,000-square-foot production facility.
  • Suzhou, China (small molecule manufacturing): Supports clinical and commercial-scale production in accordance with applicable FDA, EMA and GMP requirements.
  • Guangzhou, China (biologics and ADC manufacturing): A 1.3 million-square-foot facility supporting R&D and production of antibody-drug conjugates (ADCs) and serving as a supply hub for the Greater Bay Area, including Hong Kong.

BeOne has also been recognized by industry organizations for its innovation, including being named one of the “Top 10 Most Inventive” pharmaceutical companies by IDEA Pharma in 2025[1]. The company will continue to advance programs in hematologic malignancies and solid tumors, with Hong Kong serving as a strategic hub to support the delivery of innovative therapies globally.

1. 2025 Pharmaceutical Innovation and Invention Index, IDEA Pharma

This material is intended for the purpose of communicating disease-related knowledge and cutting-edge medical information to the public and is not intended for promotional or advertising purposes. It does not constitute a promotion or recommendation for any medication or treatment plan, nor can it serve as a substitute for the advice of medical and health professionals. If you have any questions, please consult a medical or health professional.

Forward-Looking Statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s plans, commitments, aspirations and goals related to BeOne’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this presentation is as of the date presented, and BeOne undertakes no duty to update such information unless required by law.For BeOne’s newsroom, please visit www.beonemedicines.com

Hashtag: #BeOneMedicines

The issuer is solely responsible for the content of this announcement.

About BeOne Medicines

BeOne Medicines is a global oncology company domiciled in Switzerland, focused on discovering and developing innovative treatments designed to be more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is advancing a diverse pipeline of novel therapeutics through internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to improving access to medicines for more patients. To learn more about BeOne, please visit and follow us on , , and .

About HKCT Business Awards 2026

Organized by the Hong Kong Commercial Times, the HKCT Business Awards is a representative annual event in the Hong Kong business community. It honors companies demonstrating excellence, innovation, and significant contributions to Hong Kong’s economy and society across dimensions including technological innovation and market competitiveness.

Media OutReach

The 7th Cross-Strait Financial Forum and Taiwan-Funded Enterprise Development Forum

Published

on

XIAMEN, CHINA – Media OutReach Newswire – 12 Jun 2026 – On June 12, the 7th Cross-Strait Financial Forum and Taiwan-Funded Enterprise Development Forum was held in Xiamen.The event was jointly organized by the Fujian Provincial Financial Regulatory Administration, the Xiamen Municipal Financial Regulatory Administration, and the Association of Taiwan Investment Enterprises on the Mainland, hosted by Xiamen Jinyuan Investment Group, and executed by Jinyuan Uni-President Securities. Under the theme “Three Years of Integration Embarking on a New Journey, United Development Writing a New Chapter,” the forum focused on cross-strait financial cooperation, expanded financing channels for Taiwan-funded enterprises, industrial transformation and upgrading, and financial innovation between Fujian and Taiwan. It aimed to support Fujian’s efforts to accelerate the development of the first-choice home for Taiwan compatriots and Taiwan-funded enterprises on the mainland.

This year’s forum is an important supporting event of the 18th Cross-Strait Forum. During the event, nine Fujian-Taiwan financial integration projects were signed, with a total value of RMB 9.1 billion. The projects cover a wide range of financial services across areas including cross-strait industrial cooperation, water supply security for public welfare, capacity upgrades for long-established Taiwan-funded enterprises, technology and innovation industries, and modern agriculture. These initiatives continue to unlock the benefits of financial policies, promote shared access to financial resources for Taiwan compatriots and Taiwan-funded enterprises, and inject new momentum into industrial integration between Fujian and Taiwan.

At the forum, the Cross-Strait Wealth and Asset Management Cross-Sector Alliance was officially inaugurated. Supported by Jinyuan Group and jointly proposed by its affiliated financial institutions, the alliance was co-founded by Xiamen International Trust, Jinyuan Uni-President Securities, Yuanxin Yongfeng Fund, Fubon Bank (China), Junlong Life Insurance, and Xiamen Chang Gung Hospital, among others. Centered on serving the wealth management and asset management needs of people on both sides of the Taiwan Strait, the alliance aims to build a one-stop service platform covering asset allocation for Taiwan compatriots and Taiwan-funded enterprises on the mainland, family trusts and wealth succession planning, pension finance, and healthcare protection solutions.

The forum also unveiled a series of innovative financial achievements related to Taiwan. The banking industry’s first group standard dedicated to Taiwan-related financial services on the mainland, the “Specification for Taiwan-Related Financial Services of Banking Financial Institutions,” was officially released. At the same time, the “Bailufen” Taiwan Compatriot Financial Service Platform was introduced, further enhancing financial services for Taiwan compatriots living in Fujian and supporting the development of Taiwan-funded enterprises.

Hashtag: #StraitsFinancialForum

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

Verdant Rock Receives BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings

Published

on

HAMILTON, BERMUDA – Media OutReach Newswire – 12 June 2026 – Verdant Rock Limited has received a BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings effective 12 June 2026. Combined with a Class 3B Insurer license from the Bermuda Monetary Authority (BMA), effective 6 May 2026, the company is in a strong position to extend financial guarantees on bonds and loans in emerging markets for beneficiaries globally. We provide irrevocable, unconditional, on-demand financial guarantees designed to qualify as eligible credit protection under Basel and major insurance solvency regimes. We are focused on private liabilities and do not cover sovereigns, municipalities or provinces. Bonds and loans issued by emerging market corporations and banks, structured financings, asset-backed (ABS) and mortgage-backed (MBS) exposures in securities or loan format, and project finance are all within the Company’s remit.

“The infrastructure and capital markets we are targeting have been systematically underserved over the past decade. Verdant Rock enters this space with an investment grade rating, a strong capital position, the regulatory standing, the technical capability, and the long-term commitment that issuers and their advisers have been unable to find elsewhere.”

— Tolga Uzuner, Co-Founder, Chief Executive Officer, Verdant Rock Limited

The Fitch Ratings report can be accessed here:
Fitch Rates Verdant Rock at ‘BBB+’; Outlook Stable

Verdant Rock’s Class 3B registration can be verified via the BMA’s register of regulated entities (search “Verdant Rock”): https://www.bma.bm/regulated-entities

Notes to editors: For the May 2026 licensing announcement, see https://bernews.com/2026/05/walkers-supports-verdant-rock-licensing/

This announcement is (i) for information only; (ii) not an offer or solicitation to buy or sell any security, insurance product, or financial guarantee; and (iii) not for distribution in any jurisdiction where to do so would be unlawful. Forward-looking statements are not guarantees of future results, and Verdant Rock undertakes no obligation to update them. A credit rating is not a recommendation to buy, sell or hold any security and may be subject to revision, suspension or withdrawal at any time by the assigning rating agency.

Hashtag: #VerdantRock

The issuer is solely responsible for the content of this announcement.

ABOUT VERDANT ROCK

Verdant Rock Limited is a Bermuda-based insurance company, regulated by the Bermuda Monetary Authority, providing Basel III and Solvency II compliant financial guarantees in emerging markets, designed to qualify as eligible credit protection under Basel and major insurance solvency regimes, for the benefit of institutions globally.

Continue Reading

Media OutReach

TVBS deploys AI translation for NVIDIA GTC Taipei keynote

Published

on

TAIPEI, TAIWAN – Media OutReach Newswire – 12 June 2026 – TVBS deployed its self-developed real-time AI translation system during NVIDIA CEO Jensen Huang’s keynote at GTC Taipei 2026 on June 1. The system delivered near-simultaneous Chinese subtitles that viewers initially mistook for official NVIDIA translations. The in-house technology marked a rare instance of a news organization independently developing live translation for a large-scale broadcast.

TVBS deployed its self-developed real-time AI translation system during NVIDIA CEO Jensen Huang’s keynote at GTC Taipei 2026 on June 1.

Online viewers praised the translation quality, with comments including “The quality of this real-time translation is amazing,” “The translation is incredibly fast,” and “The live speech recognition quality is surprisingly good.” Some viewers assumed the subtitles came from NVIDIA’s official translation team.

The achievement demonstrates how Taiwan’s media industry is adapting to AI-driven transformation. TVBS is positioning itself as a leader in integrating proprietary AI development with real-world broadcast applications. The company completed optimization and deployment of the system in just nine days — a process that traditionally requires months of dedicated training, according to Andy Yang, manager of TVBS AI Future Technology Department.

Yang explained that the biggest challenge in real-time translation lies in balancing “content accuracy” with “reading fluency” under extremely tight time constraints. Huang’s speaking style is highly improvisational and frequently switches between English, Mandarin and Taiwanese, while audience applause and cheering often occur simultaneously.

Applying standard off-the-shelf translation software in such an environment would likely result in sentence segmentation errors and unclear semantic interpretation, Yang said. Rather than pursuing “zero-latency” translation at all costs, TVBS designed a subtitle presentation mechanism specifically tailored to the keynote format.

Prior to the event, the TVBS team conducted extensive cross-platform testing on multiple AI translation models, evaluating latency and error rates. By introducing a carefully calibrated broadcast delay, the system gained additional time to process semantic meaning and contextual alignment. This approach enabled smoother subtitles matching natural Chinese reading habits, Yang said.

The team also built a dedicated knowledge base for NVIDIA GTC Taipei, compiling AI industry terminology, product names and technical keywords in advance. This significantly improved translation quality and the accuracy of professional content delivery. TVBS’s real-time translation system can be customized based on different broadcasting scenarios, Yang noted.

Yang emphasized that the key to the rapid nine-day deployment was cross-department collaboration. Engineering teams handled hardware tuning and signal integration, while internal technical and content teams managed ongoing model training and refinement. TVBS established a collaborative workflow integrating both technology and editorial expertise.

Through continuous iteration and adjustment, the team incorporated Taiwanese linguistic nuances and natural Chinese phrasing into the system. This enhanced fluency and readability beyond what generic AI models alone could achieve, ultimately shaping what Yang called a distinct “TVBS AI style.” The approach reflects the company’s “3T” philosophy — Truth, Trust and Technology.

In his keynote at the Taipei Music Center, Huang focused on AI infrastructure, next-generation computing platforms and NVIDIA’s latest technological roadmap. GTC Taipei 2026 attracted significant international attention as AI continues to reshape global industries. Through its own transformation journey, TVBS hopes to help lead Taiwan’s media industry into a new era shaped by AI.

Hashtag: #TVBS

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending